Title
Category
Credits
Event date
Cost
  • Research to Practice
  • 1.00 ACPE Pharmacist
  • 1.00 ASRT
  • 1.00 CTR
  • 1.00 NCPD/CNE
  • 1.00 Participation
$0.00
Innovations in breast oncology can translate to improved patient outcomes for patients with early and late-stage disease. In this webinar, Dr. Ray will discuss the latest research findings and how they can be translated into the clinical care of patients with breast cancer.
  • Research to Practice
  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Tech
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 ASRT
  • 1.00 CTR
  • 1.00 NCPD/CNE
  • 1.00 Participation
$0.00
Marc Bjurlin, DO, MSc, FACOS, gives a contemporary overview of prostate cancer screening with a focus on prostate cancer in men in North Carolina.
  • Research to Practice
  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Tech
  • 1.00 AMA PRA Category 1 Credit
  • 1.25 ASRT
  • 1.00 CTR
  • 1.00 NCPD/CNE
  • 1.00 Participation
$0.00
Hung-Jui Tan, MD, MSHPM, will review recent practice-changing research and new management recommendations for patients with prostate, kidney, bladder, and testicular cancer.
  • Research to Practice
  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Tech
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 ASRT
  • 1.00 CTR
  • 1.00 NCPD/CNE
  • 1.00 Participation
$0.00
Mark Woodcock gives a broad overview of the multidisciplinary approaches for the treatment of soft tissue sarcomas in adults, and detailed updates in management with systemic therapies. Specific attention is paid to sarcoma sub-types which may warrant special considerations.
  • Research to Practice
  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Tech
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 ASRT
  • 1.00 CTR
  • 1.00 NCPD/CNE
  • 1.00 Participation
$0.00
Daniel Richardson, MD, MA, MSc, will explore best practices to approach the care of older adults with leukemia. He will also discuss novel therapeutic options for patients with acute lymphoblastic and acute myeloid leukemia alongside practical considerations to approach shared decision-making.
  • Research to Practice
  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Tech
  • 1.00 AMA PRA Category 1 Credit
  • 1.50 ASRT
  • 1.00 CTR
  • 1.00 NCPD/CNE
  • 1.00 Participation
$0.00
Frances Collichio, MD, reviews the common and uncommon side effects of immune check point inhibitors. She also discusses the relatively new concept of delayed immune related events.
  • Research to Practice
  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Tech
  • 1.00 AMA PRA Category 1 Credit
  • 1.25 ASRT
  • 1.00 CTR
  • 1.00 NCPD/CNE
  • 1.00 Participation
$0.00
Dominique Higgins, MD, PhD, provides an overview of diagnostic criteria for primary CNS brain tumors, and the current approved and investigational treatments that are available and on the horizon.
  • Patient Centered Care
  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Tech
  • 1.00 AMA PRA Category 1 Credit
  • 1.50 ASRT
  • 1.00 CTR
  • 1.00 NCPD/CNE
  • 1.00 Participation
$0.00
Jacob Stein, MD, MPH, reviews several of the most common medical emergencies that arise when caring for patients with cancer. We highlight key aspects of presentation, diagnosis and management, with pearls for clinicians along the way.
  • Patient Centered Care
  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Tech
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 ASRT
  • 1.00 CTR
  • 1.00 NCPD/CNE
  • 1.00 Participation
$0.00
Puneet Singh Jolly, MD, PhD discusses keratinocyte neoplasms are by far the most common malignancy in the world. While surgical treatments remain the most common and most effective therapy, there are numerous emerging non-surgical techniques. We discuss these and the rationale for using such treatments, particularly in specific challenging clinical scenarios.
  • Patient Centered Care
  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Tech
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 ASRT
  • 1.00 CTR
  • 1.00 NCPD/CNE
  • 1.00 Participation
05/08/2024
$0.00
Lori Ramkissoon, PhD will review advancements in molecular oncology and demonstrate how this integration of this testing has advanced treatment strategies and improved patient outcomes for diverse cancer types.

Pages